Global Cancer Vaccine Market 2025-2035

Description

List of Tables

Cancer Vaccine Market Size, Share & Trends Analysis Report by Type (Preventive Vaccines, and Therapeutic Vaccines) by Technology (Dendritic Cell Vaccines, Conjugate Vaccines, Inactivated Vaccines, Live Attenuated Vaccines, and Recombinant Vector Vaccines) and by End-User (Hospitals and Clinics, Research Institutes, Pharmaceuticals & Biotechnology Companies, and Others) Forecast Period (2025-2035)

Industry Overview

Cancer vaccine market was valued at $11.20 billion in 2024 and is projected to reach $36.14 billion by 2035, growing at a CAGR of 11.3% during the forecast period (2025-2035). The market growth in cancer therapies is driven by several factors, such as the rising prevalence of cancer globally, advancements in immunotherapy and mRNA technologies, increased investment in R&D by pharmaceutical companies, and a shift towards personalized medicine tailored to individual patient needs. Additionally, growing patient awareness and supportive regulatory frameworks, such as the FDA's breakthrough therapy designation, further promote market expansion.

Market Dynamics

Rising Cancer Incidence

The increasing prevalence of cancer worldwide is a major driver for the growth of the cancer vaccine market. According to the World Health Organization, cancer is a leading cause of death globally, with an estimated 20 million new cases and 9.7 million deaths in 2022

Advancements in Immunotherapy

Recent developments in immunotherapy, particularly in personalized and neoantigen-based vaccines, are propelling the market forward. These therapies aim to stimulate the immune system to target and destroy cancer cells more effectively.

Supportive Government Initiatives

Governments worldwide are implementing national immunization programs to combat cancer. For instance, Pakistan has vaccinated approximately 9 million girls against the human papillomavirus (HPV), aiming to reduce cervical cancer incidence.

Market Segmentation

Based on the type, the market is segmented into preventive vaccines and therapeutic vaccines.
Based on the technology, the market is segmented into dendritic cell vaccines, conjugate vaccines, inactivated vaccines, live attenuated vaccines, and recombinant vector vaccines.
Based on the end user, the market is segmented into hospitals and clinics, research institutes, pharmaceuticals & biotechnology companies, and others.

Preventive Vaccines Largest Segment in the Global Cancer Vaccine Market

The preventive vaccines segment holds the largest share in the global cancer vaccine market. This includes vaccines such as the HPV and Hepatitis B vaccines, which are widely used to prevent cancers like cervical and liver cancer. The success of these vaccines in reducing cancer incidence has led to their widespread adoption and significant market share.

Regional Outlook

The global cancer vaccine market is further divided by region, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

North America Maintains Strong Market Position

In North America, the US dominates the global cancer vaccine Market with a major share, driven by its advanced healthcare infrastructure, strong biotechnology and pharmaceutical presence, and significant investments in oncology research and immunotherapy development. The country's leadership is largely attributed to its robust R&D ecosystem supported by both government and private sector funding through organizations such as the National Cancer Institute (NCI) and the National Institutes of Health (NIH), which continuously promote innovation in preventive and therapeutic cancer vaccines. Additionally, the presence of major biotechnology companies such as Moderna, Gilead Sciences, Bristol Myers Squibb, and Merck & Co., which have pioneered groundbreaking immuno-oncology products like the HPV vaccine Gardasil and mRNA-based vaccine technologies, strengthens the US position in this market.

High cancer prevalence and growing demand for personalized treatment approaches have also accelerated the adoption of cancer vaccines for both prevention and therapy. Favorable regulatory policies by the US Food and Drug Administration (FDA), along with faster approval processes for breakthrough therapies, have encouraged continuous clinical trials and the commercialization of new vaccine candidates. Moreover, increasing collaborations between academic institutions and biopharma companies for next-generation vaccines, coupled with rising awareness about immunization and early cancer detection, continue to fuel market growth. As a result, the US maintains its dominant role in setting global benchmarks for innovation, clinical advancement, and commercialization within the cancer vaccine landscape.

Market Players Outlook

The major companies operating in the global cancer vaccine market include GlaxoSmithKline plc (GSK), Merck & Co., Inc., Moderna, Inc., Pfizer, Inc., Sanofi S.A., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

In August 2025, BioNTech announced plans to invest up to £1 billion ($1.33 billion) in the United Kingdom over the next decade to expand its research and development activities, including personalized cancer therapies.
In September 2025, Bristol Myers Squibb entered into an $11 billion partnership with BioNTech to co-develop and commercialize a promising cancer drug, BNT327, which shows potential to outperform existing therapies.
In September 2025, Enteromix, a personalized mRNA-based cancer vaccine developed in Russia, showed 100% efficacy and safety in clinical trials. It trains the immune system to target and eliminate cancer cells without serious side effects, utilizing similar technology to that of COVID-19 vaccines. The vaccine is currently awaiting final approval from the Ministry of Health for public use.
In September 2025, Pakistan successfully vaccinated approximately 9 million girls against HPV, aiming to reduce cervical cancer incidence, despite challenges posed by misinformation.

The Report Covers:

Market value data analysis of 2024 and forecast to 2035.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global cancer vaccine market. Based on the availability of data, information related to new products and relevant news is also available in the report.

Product Code: OMR2023991

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Global Cancer Vaccine Market Sales Analysis - Type| Technology | End-User ($ Million)
Cancer Vaccine Market Sales Performance of Top Countries
1.1. Research Methodology
Primary Research Approach
Secondary Research Approach
1.2. Market Snapshot

2. Market Overview and Insights

2.1. Scope of the Study
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Cancer Vaccine Market Trends
- 2.2.2. Market Recommendations

3. Market Determinants

3.1. Market Drivers
- 3.1.1. Drivers For Global Cancer Vaccine Market: Impact Analysis
3.2. Market Pain Points and Challenges
- 3.2.1. Restraints For Global Cancer Vaccine Market: Impact Analysis
3.3. Market Opportunities
- 3.3.1. Opportunities For Global Cancer Vaccine Market: Impact Analysis

4. Competitive Landscape

4.1. Competitive Dashboard - Cancer Vaccine Market Revenue and Share by Manufacturers
Cancer Vaccine Comparison Analysis
Top Market Player Ranking Matrix
4.2. Key Company Analysis
- 4.2.1. GlaxoSmithKline plc (GSK)
  - 4.2.1.1. Overview
  - 4.2.1.2. Product Portfolio
  - 4.2.1.3. Financial Analysis (Subject to Data Availability)
  - 4.2.1.4. SWOT Analysis
  - 4.2.1.5. Business Strategy
- 4.2.2. Merck & Co., Inc.
  - 4.2.2.1. Overview
  - 4.2.2.2. Product Portfolio
  - 4.2.2.3. Financial Analysis (Subject to Data Availability)
  - 4.2.2.4. SWOT Analysis
  - 4.2.2.5. Business Strategy
- 4.2.3. Moderna, Inc.
  - 4.2.3.1. Overview
  - 4.2.3.2. Product Portfolio
  - 4.2.3.3. Financial Analysis (Subject to Data Availability)
  - 4.2.3.4. SWOT Analysis
  - 4.2.3.5. Business Strategy
- 4.2.4. Pfizer, Inc.
  - 4.2.4.1. Overview
  - 4.2.4.2. Product Portfolio
  - 4.2.4.3. Financial Analysis (Subject to Data Availability)
  - 4.2.4.4. SWOT Analysis
  - 4.2.4.5. Business Strategy
- 4.2.5. Sanofi S.A
  - 4.2.5.1. Overview
  - 4.2.5.2. Product Portfolio
  - 4.2.5.3. Financial Analysis (Subject to Data Availability)
  - 4.2.5.4. SWOT Analysis
  - 4.2.5.5. Business Strategy
4.3. Top Winning Strategies by Market Players
- 4.3.1. Merger and Acquisition
- 4.3.2. Product Launch
- 4.3.3. Partnership And Collaboration

5. Global Cancer Vaccine Market Sales Analysis By Type ($ Million)

5.1. Preventive Vaccines
5.2. Therapeutic vaccines

6. Global Cancer Vaccine Market Sales Analysis By Technology ($ Million)

6.1. Dendritic Cell Vaccines
6.2. Conjugate Vaccines
6.3. Inactivated Vaccines
6.4. Live Attenuated Vaccines
6.5. Recombinant Vector Vaccines

7. Global Cancer Vaccine Market Sales Analysis By End-User ($ Million)

7.1. Hospitals and Clinics
7.2. Research Institutes
7.3. Pharmaceuticals & Biotechnology Companies
7.4. Others

8. Regional Analysis

8.1. North American Cancer Vaccine Market Sales Analysis - Type| Technology | End-User ($ Million)
Macroeconomic Factors for North America
- 8.1.1. United States
- 8.1.2. Canada
8.2. European Cancer Vaccine Market Sales Analysis - Type| Technology | End-User ($ Million)
Macroeconomic Factors for Europe
- 8.2.1. UK
- 8.2.2. Germany
- 8.2.3. Italy
- 8.2.4. Spain
- 8.2.5. France
- 8.2.6. Russia
- 8.2.7. Rest of Europe
8.3. Asia-Pacific Cancer Vaccine Market Sales Analysis - Type| Technology | End-User ($ Million)
Macroeconomic Factors for Asia-Pacific
- 8.3.1. China
- 8.3.2. Japan
- 8.3.3. South Korea
- 8.3.4. India
- 8.3.5. Australia & New Zealand
- 8.3.6. ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- 8.3.7. Rest of Asia-Pacific
8.4. Rest of the World Cancer Vaccine Market Sales Analysis - Type| Technology | End-User ($ Million)
Macroeconomic Factors for the Rest of the World
- 8.4.1. Latin America
- 8.4.2. Middle East and Africa

9. Company Profiles

9.1. Antigenics
- 9.1.1. Quick Facts
- 9.1.2. Company Overview
- 9.1.3. Product Portfolio
- 9.1.4. Business Strategies
9.2. Avax Technologies
- 9.2.1. Quick Facts
- 9.2.2. Company Overview
- 9.2.3. Product Portfolio
- 9.2.4. Business Strategies
9.3. BioNTech
- 9.3.1. Quick Facts
- 9.3.2. Company Overview
- 9.3.3. Product Portfolio
- 9.3.4. Business Strategies
9.4. CureVac
- 9.4.1. Quick Facts
- 9.4.2. Company Overview
- 9.4.3. Product Portfolio
- 9.4.4. Business Strategies
9.5. Dendreon Pharmaceuticals LLC
- 9.5.1. Quick Facts
- 9.5.2. Company Overview
- 9.5.3. Product Portfolio
- 9.5.4. Business Strategies
9.6. GlaxoSmithKline Plc
- 9.6.1. Quick Facts
- 9.6.2. Company Overview
- 9.6.3. Product Portfolio
- 9.6.4. Business Strategies
9.7. Immatics
- 9.7.1. Quick Facts
- 9.7.2. Company Overview
- 9.7.3. Product Portfolio
- 9.7.4. Business Strategies
9.8. Inovio Pharmaceuticals
- 9.8.1. Quick Facts
- 9.8.2. Company Overview
- 9.8.3. Product Portfolio
- 9.8.4. Business Strategies
9.9. Ipsen
- 9.9.1. Quick Facts
- 9.9.2. Company Overview
- 9.9.3. Product Portfolio
- 9.9.4. Business Strategies
9.10. JW CreaGene
- 9.10.1. Quick Facts
- 9.10.2. Company Overview
- 9.10.3. Product Portfolio
- 9.10.4. Business Strategies
9.11. Merck & Co., Inc.
- 9.11.1. Quick Facts
- 9.11.2. Company Overview
- 9.11.3. Product Portfolio
- 9.11.4. Business Strategies
9.12. Moderna Inc.
- 9.12.1. Quick Facts
- 9.12.2. Company Overview
- 9.12.3. Product Portfolio
- 9.12.4. Business Strategies
9.13. Northwest Biotherapeutics
- 9.13.1. Quick Facts
- 9.13.2. Company Overview
- 9.13.3. Product Portfolio
- 9.13.4. Business Strategies
9.14. OncoTherapy Science
- 9.14.1. Quick Facts
- 9.14.2. Company Overview
- 9.14.3. Product Portfolio
- 9.14.4. Business Strategies
9.15. Pfizer, Inc.
- 9.15.1. Quick Facts
- 9.15.2. Company Overview
- 9.15.3. Product Portfolio
- 9.15.4. Business Strategies
9.16. Replimune Group
- 9.16.1. Quick Facts
- 9.16.2. Company Overview
- 9.16.3. Product Portfolio
- 9.16.4. Business Strategies
9.17. Sanofi S.A
- 9.17.1. Quick Facts
- 9.17.2. Company Overview
- 9.17.3. Product Portfolio
- 9.17.4. Business Strategies
9.18. Serum Institute of India Pvt. Ltd.
- 9.18.1. Quick Facts
- 9.18.2. Company Overview
- 9.18.3. Product Portfolio
- 9.18.4. Business Strategies
9.19. Shanghai Zerun Biotechnology Co., Ltd.
- 9.19.1. Quick Facts
- 9.19.2. Company Overview
- 9.19.3. Product Portfolio
- 9.19.4. Business Strategies
9.20. Vaccinogen
- 9.20.1. Quick Facts
- 9.20.2. Company Overview
- 9.20.3. Product Portfolio
- 9.20.4. Business Strategies
9.21. Verity Pharmaceuticals, Inc.
- 9.21.1. Quick Facts
- 9.21.2. Company Overview
- 9.21.3. Product Portfolio
- 9.21.4. Business Strategies
9.22. Wantai BioPharm
- 9.22.1. Quick Facts
- 9.22.2. Company Overview
- 9.22.3. Product Portfolio
- 9.22.4. Business Strategies